<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Bramble: Tirzepatide</title>
    <link>https://news.ketelle.co.uk/entities/tirzepatide</link>
    <description>Stories involving Tirzepatide, told neutrally, with how each side covers them.</description>
    <language>en-gb</language>
    <atom:link href="https://news.ketelle.co.uk/entities/tirzepatide/feed.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>Tirzepatide plus eloralintide produces larger weight loss in mid-stage diabetes trial</title>
      <link>https://news.ketelle.co.uk/stories/tirzepatide-combined-with-second-drug-boosts-weight-loss-study-finds</link>
      <guid isPermaLink="true">https://news.ketelle.co.uk/stories/tirzepatide-combined-with-second-drug-boosts-weight-loss-study-finds</guid>
      <pubDate>Wed, 30 Sep 2026 15:41:08 +0100</pubDate>
      <category>Health</category>
      <description>Eli Lilly reported at a European diabetes meeting that tirzepatide combined with the amylin drug eloralintide led to greater weight loss than tirzepatide alone in people with type 2 diabetes. Higher dropout and side effects raise tolerability questions. (2 outlets: 0 left · 2 centre · 0 right)</description>
      <media:content url="https://www.newscientist.com/wp-content/uploads/2026/09/SEI_314688651.jpg" medium="image"/>
    </item>
  </channel>
</rss>
